Assessment of quality of life in patients with advanced non-small cell
               lung carcinoma treated with a combination of carboplatin and paclitaxel

Avelino, Camila Uanne Resende; Cardoso, Rafael Marques; Aguiar, Suzana Sales de; Silva, Mário Jorge Sobreira da

doi:10.1590/S1806-37132015000004367

Camila Uanne Resende Avelino

Pharmacist. Multiprofessional Residence Program in Oncology, José Alencar Gomes da Silva National Cancer Institute, Rio de Janeiro, Brazil

Rafael Marques Cardoso

Pharmacist. Chemotherapy Center, Cancer Hospital I, José Alencar Gomes da Silva National Cancer Institute, Rio de Janeiro, Brazil

Suzana Sales de Aguiar

Technologist. Department of Clinical Epidemiology, José Alencar Gomes da Silva National Cancer Institute, Rio de Janeiro, Brazil

Mário Jorge Sobreira da Silva

Pharmaceutical Technologist. José Alencar Gomes da Silva National Cancer Institute, Rio de Janeiro, Brazil

Correspondence to: Camila Uanne Resende Avelino. Liga Norte Riograndense Contra o Câncer, Rua Silvio Pelico, 181, Alecrim, CEP 59040-150, Natal, RN, Brasil. Tel: 55 84 4009-5689. E-mail: camila_uanne@hotmail.com

Figures (3)
Tables (2)

Thumbnail

Figure 1 -
Changes in mean European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) functional scale scores. In A, differences in mean EORTC QLQ-C30 scores between the 1st and 2nd cycles of chemotherapy (n = 16); in B, differences in mean EORTC QLQ-C30 scores between the 2nd and 4th cycles of chemotherapy (n = 13); and in C, differences in mean EORTC QLQ-C30 scores between the 1st and 4th cycles of chemotherapy (n = 13). QoL: quality of life.

Thumbnail

Figure 2 -
Changes in mean European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) symptom scores. In A, differences in mean EORTC QLQ-C30 scores between the 1st and 2nd cycles of chemotherapy (n = 16); in B, differences in mean EORTC QLQ-C30 scores between the 2nd and 4th cycles of chemotherapy (n = 13); and in C, differences in mean EORTC QLQ-C30 scores between the 1st and 4th cycles of chemotherapy (n = 13).

Thumbnail

Figure 3 -
Changes in mean European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire supplemental lung cancer-specific module (EORTC QLQ-LC13) scores. In A, differences in mean EORTC QLQ-LC13 scores between the 1st and 2nd cycles of chemotherapy (n = 16); in B, differences in mean EORTC QLQ-LC13 scores between the 2nd and 4th cycles of chemotherapy (n = 13); and in C, differences in mean EORTC QLQ-LC13 scores between the 1st and 4th cycles of chemotherapy (n = 13).

Thumbnail

Table 1 -
Sociodemographic and clinical characteristics of the study participants.

Thumbnail

Table 2 -
Mean European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire supplemental lung cancer-specific module scores during chemotherapy.

Patient characteristic	n	%
Age, years
< 65	6	37.5
≥ 65	10	62.5
Gender
Male	9	56.3
Female	7	43.8
Race
White	9	56.3
Black	3	18.8
Others	4	25.0
Histological type of NSCLC
Adenocarcinoma	9	56.3
Others	7	43.8
Stage at diagnosis
IIIB	6	37.5
IV	10	62.5
Performance status
1	12	75.0
2	4	25.0
Comorbidities
Yes	9	56.3
No	7	43.8
Number of drugs used
< 4	1	6.3
5-7	9	56.3
8-10	6	37.5
Family history of cancer
Yes	8	50.0
No	8	50.0
History of smoking
Yes	13	81.3
No	3	18.8
History of alcoholism
Yes	8	50.0
No	8	50.0

Questionnaire	1st cycle (n = 16)		2nd cycle (n = 16)		4th cycle (n = 13)
Module/Item	Mean ± SD	Median	Mean ± SD	Median	Mean ± SD	Median
EORTC QLQ-C30
Functional scale
Global health status/QoL	67.2 ± 28.0	62.5	73.4 ± 21.6	79.2	77.6 ± 21.9	83.3
Physical functioning	59.8 ± 27.7	60.0	80.4 ± 18.6	83.3	81.5 ± 20.9	93.3
Role functioning	70.7 ± 39.7	91.5	79.2 ± 34.2	100.0	91.0 ± 22.2	100.0
Cognitive functioning	79.0 ± 35.9	100.0	85.4 ± 24.2	100.0	73.1 ± 30.1	83.3
Emotional functioning	63.9 ± 28.6	75.0	73.4 ± 25.5	75.0	66.0 ± 32.2	83.3
Social functioning	91.6 ± 16.3	100.0	96.9 ± 12.5	100.0	91.0 ± 18.8	100.0
Symptom scale
Fatigue	55.6 ± 36.7	66.7	69.5 ± 27.4	66.7	77.8 ± 20.8	88.9
Pain	60.4 ± 35.4	58.4	80.2 ± 28.0	81.7	78.2 ± 23.9	83.3
Dyspnea	62.5 ± 40.1	66.7	75.0 ± 35.5	100.0	74.4 ± 38.9	100.0
Insomnia	77.1 ± 35.9	100.0	72.9 ± 38.9	100.0	71.8 ± 38.1	100.0
Appetite loss	41.7 ± 46.4	16.5	79.2 ± 40.1	100.0	79.5 ± 39.8	100.0
Nausea/vomiting	91.7 ± 16.1	100.0	89.6 ± 21.0	100.0	92.3 ± 18.8	100.0
Constipation	47.9 ± 50.1	33.4	64.6 ± 44.7	100.0	76.9 ± 43.9	100.0
Diarrhea	100.0 ± 0.0	100.0	91.7 ± 25.8	100.0	92.3 ± 27.7	100.0
Financial difficulties	70.8 ± 41.9	100.0	83.3 ± 32.2	100.0	87.2 ± 25.6	100.0
QLQ-LC13
Dyspnea	68.8 ± 37.0	83.4	75.7 ± 32.5	88.9	86.3 ± 25.3	100.0
Cough	47.9 ± 40.3	50.0	58.3 ± 35.5	66.7	48.7 ± 44.3	66.7
Hemoptysis	93.8 ± 13.4	100.0	87.5 ± 24.0	100.0	94.9 ± 18.5	100.0
Sore mouth	89.6 ± 29.1	100.0	97.9 ± 8.3	100.0	94.9 ± 12.5	100.0
Dysphagia	87.5 ± 24.0	100.0	93.8 ± 18.1	100.0	82.3 ± 27.7	100.0
Peripheral neuropathy	83.3 ± 29.8	100.0	77.1 ± 39.8	100.0	76.9 ± 39.4	100.0
Alopecia	97.9 ± 8.3	100.0	22.9 ± 33.8	0.0	53.8 ± 51.9	100.0
Chest pain	58.3 ± 46.4	83.4	85.4 ± 27.1	100.0	82.1 ± 37.6	100.0
Arm/shoulder pain	60.4 ± 45.9	83.4	81.3 ± 29.7	100.0	84.6 ± 29.2	100.0
Pain in other body parts	58.3 ± 49.4	100.0	77.1 ± 35.9	100.0	71.8 ± 42.7	100.0

[1] Correspondence to: Camila Uanne Resende Avelino. Liga Norte Riograndense Contra o Câncer, Rua Silvio Pelico, 181, Alecrim, CEP 59040-150, Natal, RN, Brasil. Tel: 55 84 4009-5689. E-mail: camila_uanne@hotmail.com

Brasil

Brasil

Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel^* * Study carried out at the José Alencar Gomes da Silva National Cancer Institute, Rio de Janeiro, Brazil.

OBJECTIVE:

METHODS:

RESULTS:

CONCLUSIONS:

Brasil

Brasil

Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel* * Study carried out at the José Alencar Gomes da Silva National Cancer Institute, Rio de Janeiro, Brazil.

OBJECTIVE:

METHODS:

RESULTS:

CONCLUSIONS:

Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel^* * Study carried out at the José Alencar Gomes da Silva National Cancer Institute, Rio de Janeiro, Brazil.